Craft

Inhibikase Therapeutics

Stock Price

$2.6

2024-10-29

Market Capitalization

$173.6 M

2024-10-29

Revenue

$260.5 K

FY, 2023

Inhibikase Therapeutics Summary

Company Summary

Overview
Inhibikase Therapeutics is a pharmaceutical company that develops neurodegenerative disease treatments. It provides a re-engineering approach with a metabolism preserved (RAMP) drug innovation engine developing protein kinase inhibitors for the treatment of kinase-sensitive CNS diseases.
Type
Public
Status
Active
Founded
2008
HQ
Atlanta, GA, US | view all locations
Website
https://www.inhibikase.com
Cybersecurity rating
Sectors

Key People

  • Dan Williams, Controller

    • Joseph Frattaroli, CFO

      • C. Warren Olanow, Interim Chief Medical Officer

        • Paul C. Grint

          Paul C. Grint, Director

          Operating MetricsView all

          Preclinical Phase Products

          4

          Q3, 2020

          Phase I Trials Products

          1

          Q3, 2020

          LocationsView all

          2 locations detected

          • Atlanta, GA HQ

            United States

            3350 Riverwood Pkwy #1900

          • Lexington, MA

            United States

            1 Cranberry Hill Suite 200

          Inhibikase Therapeutics Financials

          Summary Financials

          Net income (FY, 2025)
          ($48.3M)
          Cash (FY, 2025)
          $178.8M
          EBIT (FY, 2025)
          ($52.0M)

          Footer menu